ANI PHARMACEUTICALS INC (ANIP)
Sector: Health Care
2026 Annual Meeting Analysis
ANI PHARMACEUTICALS INC · Meeting: May 21, 2026
Directors FOR
7
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Haughey has served since May 2018 and brings deep pharmaceutical industry legal and financial expertise; ANIP's 3-year price return of 112.5% outperforms the XLV sector ETF by +94.8 percentage points, well above the 65pp threshold required to trigger a TSR-based against vote, so no performance concern applies.
Lalwani has served as CEO and director since September 2020 and is the operational link between management and the board; ANIP's 3-year stock return far outpaces the XLV benchmark (+94.8pp vs. 65pp trigger threshold), so no TSR-based concern applies to him as a director.
Leonard joined in August 2023, fewer than 24 months before the filing date, placing him within the new-director exemption period under the policy; he also brings extensive pharmaceutical and pharmacy leadership experience relevant to ANI's business.
Pera has served since August 2020 and brings extensive generics pharmaceutical industry leadership; ANIP's 3-year stock outperformance versus XLV (+94.8pp) is far below the 65pp trigger threshold needed to raise a TSR concern, so no against vote is warranted.
Shanmugam has served since November 2021 and leads R&D and operations as an employee director with deep pharmaceutical formulation expertise; ANIP's strong 3-year stock performance versus the XLV ETF (+94.8pp gap, threshold 65pp) means the TSR trigger does not apply.
Tannenbaum has served since March 2022 and brings extensive biopharma executive and multi-board experience; ANIP's 3-year stock return significantly outperforms XLV, clearing the strong-positive TSR threshold and ruling out any performance-based concern.
Thoma has served since August 2020 and contributes broad pharmaceutical industry leadership as Audit Committee Chair; ANIP's 3-year price return of 112.5% exceeds XLV by +94.8pp, well above the 65pp trigger needed to vote against, so no TSR concern applies.
All seven director nominees receive a FOR vote. ANIP's 3-year stock return of 112.5% outpaces the XLV healthcare sector ETF by approximately 95 percentage points, far exceeding the 65-percentage-point threshold required to trigger an against vote for directors under the strong-positive TSR category. Matthew Leonard, who joined in August 2023, also qualifies for the 24-month new-director exemption. No overboarding, attendance, independence, or qualification concerns were identified for any nominee.
Say on Pay
✓ FORCEO
Nikhil Lalwani
Total Comp
$10,278,620
Prior Support
89.6%%
CEO Nikhil Lalwani received total compensation of $10,278,620 in 2025, which is within a reasonable range for a CEO at a diversified pharmaceutical company of ANI's size and complexity given its record revenue growth of 43.8% and transition into rare disease. The pay mix is heavily variable and performance-linked: approximately 76% of total CEO compensation came from equity awards and performance-based cash bonuses, well above the 50-60% variable pay threshold the policy requires, and the performance stock awards (which represent 25% of equity grants) use a three-year adjusted EBITDA growth rate and relative total shareholder return versus an S&P index as performance metrics — meaningful long-term conditions. Pay-for-performance alignment is strong: ANIP's 3-year stock return of 112.5% dramatically outperforms the XLV healthcare sector ETF benchmark (+94.8pp), and the company's 2023 performance stock awards paid out at 200% of target based on above-maximum EBITDA growth and TSR above the 75th percentile, demonstrating that above-target incentive pay was directly earned through superior shareholder outcomes. The company also has a formal clawback policy compliant with Dodd-Frank, and last year's say-on-pay vote received 89.6% support — no concerns about shareholder responsiveness arise.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
0 yrs
Audit Fees
$1,716,375
Non-Audit Fees
$0
The company is ratifying Ernst & Young LLP, which was engaged on April 1, 2026 and is a Big 4 firm appropriate for ANI's $1.8 billion market cap; the fee table shown covers the prior auditor EisnerAmper's 2025 fees, which consisted entirely of core audit fees with zero non-audit, audit-related, or tax fees, producing a non-audit ratio of 0% — well within the 50% policy threshold. EY's tenure is effectively zero (brand-new engagement), so no long-tenure concern applies.
Overall Assessment
This is a straightforward annual meeting ballot for ANI Pharmaceuticals with no contested or problematic proposals. All seven director nominees receive FOR votes supported by strong 3-year stock outperformance versus the XLV healthcare ETF, Ernst & Young is ratified as incoming auditor with clean fee disclosures and no independence concerns, and the say-on-pay vote is supported by a well-structured, heavily variable pay program that demonstrably rewarded executives for genuine outperformance of shareholders and peers.